Why Indian drugmakers are losing pricing power in the US
LiveMint

Indian drugmakers are losing pricing power in the United States due to powerful buyers and fading generic launches.
Powerful buyers, the end of limits on generic Revlimid and fast-fading
launches are squeezing Indian drugmakers' US business. Complex products offer
a way to protect pricing power, but developing them requires higher R&D
spending and years of investment before they can replace lost revenue.



